CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ±èµ¿Çö
  • ÇǺΰúÀå
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °Ç¼±/ÇǺξÏ/»ö¼Ò¼ºÁúȯ/Å»¸ð/µÎÇÇÁúȯ
  • Á÷ À§: ±³¼ö(ÇǺΰúÀå)
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßž·Î 59
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
145 (±¹³»)KCIÈĺ¸ Ä¡À¯µÈ ´ë»óÆ÷Áø ºÎÀ§¿¡ ¹ß»ýÇÑ ÆÇ»ó°Ç¼±: Wolf¡¯s Isotopic Response
144 (±¹³»)KCIÈĺ¸ Àü½Å°í¸§¹°Áý°Ç¼± ȯÀÚ¿¡¼­ cyclosporine Ä¡·á Áß ¹ß»ýÇÑ Kaposi ¼öµÎ ¸ð¾ç¹ßÁø
143 (±¹³»)SCIE Comparison of the treatment outcomes of photodynamic therapy and ingenol mebutate in Bowen¡¯s disease: A retrospective observational study
142 (±¹¿Ü)SCI Immune tolerance of tissue-engineered skin produced with allogeneic or xenogeneic fibroblasts and syngeneic keratinocytes grafted on mice
141 (±¹³»)KCIÈĺ¸ °Ç¼±°üÀý¿°À» µ¿¹ÝÇÑ °Ç¼± ȯÀÚ¿¡¼­ adalimumab Ä¡·á Áß ¹ß»ýÇÑ ±Þ¼º °ñ¼ö¼º¹éÇ÷º´ 1¿¹
140 (±¹¿Ü)SCI A Case of Interstitial Lung Disease and Autoimmune Thyroiditis Associated with Ustekinumab
139 (±¹³»)KCI ÃÖ±Ù 11³â°£(2006¡­2016) °æ±â µ¿³²ºÎ Áö¿ªÀÇ ÁÖ¿ä ÇǺξǼºÁ¾¾ç°ú ÇǺξÏÀü±¸Áõ¿¡ °üÇÑ Åë°èÀû °íÂû
138 (±¹³»)SCIE Anti-wrinkle efficacy of cross-linked hyaluronic acid-based micropatch with acetyl hexapeptide-8 and epidermal growth factor on Asian skin
137 (±¹¿Ü)SCI Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes
136 (±¹³»)SCOPUS Vanishing Bile Duct Syndrome°ú µ¿¹ÝµÇ¾î ³ªÅ¸³­ Stevens-Johnson Syndrome 1¿¹
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729